Can-Fite Begins Phase II Trials for Treatment of Symptoms of Keratitis Sicca (Dry-Eye Syndrome)
Wednesday, January 31st, 2007Can-Fite BioPharma Ltd. (TASE:CFBI) has begun Phase II clinical trials for its CF101 drug for the treatment of symptoms of keratitis sicca (dry-eye syndrome).
































